BioStem Technologies, Inc. (BSEM)
OTCMKTS
· Delayed Price · Currency is USD
12.60
-0.40 (-3.08%)
Mar 4, 2025, 3:30 PM EST
BioStem Technologies Revenue
BioStem Technologies had revenue of $82.56M in the quarter ending September 30, 2024, with 2,258.93% growth. This brings the company's revenue in the last twelve months to $210.49M, up 3,445.26% year-over-year. In the year 2023, BioStem Technologies had annual revenue of $16.69M with 142.69% growth.
Revenue (ttm)
210.49M
Revenue Growth
+3,445.26%
P/S Ratio
0.99
Revenue / Employee
6.38M
Employees
33
Market Cap
216.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 16.69M | 9.81M | 142.69% |
| Dec 31, 2022 | 6.88M | 2.53M | 58.38% |
| Dec 31, 2021 | 4.34M | 4.03M | 1,284.88% |
| Dec 31, 2017 | 313.45K | -293.78K | -48.38% |
| Dec 31, 2016 | 607.22K | 455.69K | 300.71% |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
| Dec 31, 2011 | Pro | Pro | Pro |
| Dec 31, 2010 | Pro | Pro | Pro |
| Dec 31, 2009 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| SS Innovations International | 16.04M |
| Veradigm | 1.53B |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| SANUWAVE Health | 29.30M |
| Silence Therapeutics | 54.16M |
BioStem Technologies News
- 8 days ago - BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers - GlobeNewsWire
- 7 weeks ago - BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje® - GlobeNewsWire
- 2 months ago - BioStem Technologies CEO to Present at Biotech Showcase 2025 - GlobeNewsWire
- 3 months ago - BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts - GlobeNewsWire
- 3 months ago - BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global - GlobeNewsWire
- 3 months ago - Long-Term, BioStem Technologies Still A Promising Growth Stock - Seeking Alpha
- 3 months ago - BioStem Technologies, Inc. (BSEM) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions - GlobeNewsWire